Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

592 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Association between Immune-Related Adverse Events and Survival in 319 Stage IV Melanoma Patients Treated with PD-1-Based Immunotherapy: An Approach Based on Clinical Chemistry.
Serna-Higuita LM, Amaral T, Forschner A, Leiter U, Flatz L, Seeber O, Thomas I, Garbe C, Eigentler TK, Martus P. Serna-Higuita LM, et al. Among authors: martus p. Cancers (Basel). 2021 Dec 6;13(23):6141. doi: 10.3390/cancers13236141. Cancers (Basel). 2021. PMID: 34885249 Free PMC article.
Tumor mutation burden and circulating tumor DNA in combined CTLA-4 and PD-1 antibody therapy in metastatic melanoma - results of a prospective biomarker study.
Forschner A, Battke F, Hadaschik D, Schulze M, Weißgraeber S, Han CT, Kopp M, Frick M, Klumpp B, Tietze N, Amaral T, Martus P, Sinnberg T, Eigentler T, Keim U, Garbe C, Döcker D, Biskup S. Forschner A, et al. Among authors: martus p. J Immunother Cancer. 2019 Jul 12;7(1):180. doi: 10.1186/s40425-019-0659-0. J Immunother Cancer. 2019. PMID: 31300034 Free PMC article. Clinical Trial.
TMB and BRAF mutation status are independent predictive factors in high-risk melanoma patients with adjuvant anti-PD-1 therapy.
Eckardt J, Schroeder C, Martus P, Armeanu-Ebinger S, Kelemen O, Gschwind A, Bonzheim I, Eigentler T, Amaral T, Ossowski S, Rieß O, Flatz L, Garbe C, Forschner A. Eckardt J, et al. Among authors: martus p. J Cancer Res Clin Oncol. 2023 Feb;149(2):833-840. doi: 10.1007/s00432-022-03939-w. Epub 2022 Feb 22. J Cancer Res Clin Oncol. 2023. PMID: 35192052 Free PMC article.
Influence of 18F-FDG PET/CT on clinical management and outcome in patients with advanced melanoma not primarily selected for surgery based on a linked evidence approach.
Olthof SC, Forschner A, Martus P, Garbe C, Nikolaou K, la Fougère C, Gückel B, Vach W, Pfannenberg C. Olthof SC, et al. Among authors: martus p. Eur J Nucl Med Mol Imaging. 2020 Sep;47(10):2313-2321. doi: 10.1007/s00259-020-04733-x. Epub 2020 Mar 2. Eur J Nucl Med Mol Imaging. 2020. PMID: 32123968
592 results